Gil Blum is ranked #2406 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

NDM

Gil Blum

Q: How accurate are Gil Blum's stock ratings?

About 43% of Gil's ratings were profitable over a one-year hold, with an average return of -1.9% per rating, measured by 13Foresight from historical prices.

Needham

Wall Street Analyst

★★☆☆☆

#2406

on 13Foresight · ranked by our own returns

43%

Success Rate

+3.0%

Average Return

35 of 81 calls profitable · +0.1% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 43% of Gil Blum's ratings turned a profit when each position was held for 2 year — averaging +3.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

145 Buy 21 Hold 9 Sell

Gil's Stock Coverage 28 ratings · 2026-11-11

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	2-Yr Return	vs S&P 500 ⓘ
ARTV Artiva Biotherapeutics, Inc.	Oct 27, 2026	HOLD	Buy +394.4% avg upside 8 analysts	$1.00 76.09% Downside	-2.8%	·
RXRX Recursion Pharmaceuticals	Oct 19, 2026	BUY	Buy +92.7% avg upside 12 analysts	$8.00 98.60% Upside	-1.7%	·
RCKT Rocket Pharmaceuticals	Oct 07, 2026	BUY	Buy +546.4% avg upside 30 analysts	$9.00 268.93% Upside	-0.2%	·
FATE Fate Therapeutics	Oct 05, 2026	HOLD	Buy +482.8% avg upside 31 analysts	—	-24.3%	·
NKTX Nkarta	Oct 05, 2026	BUY	Strong Buy +1080.5% avg upside 16 analysts	$11.00 605.17% Upside	-31.6%	·
CRSP Crispr Therapeutics AG	Oct 05, 2026	BUY	Buy +45.6% avg upside 41 analysts	$82.00 59.52% Upside	-21.4%	·
AUTL Autolus Therapeutics	Oct 02, 2026	BUY	Strong Buy +599.0% avg upside 16 analysts	$10.00 557.92% Upside	-23.9%	·
CELC Celcuity	Sep 30, 2026	BUY	Strong Buy +82.6% avg upside 18 analysts	$134.00 93.79% Upside	-15.7%	·
RNAC Cartesian Therapeutics	Sep 29, 2026	BUY	Strong Buy +378.5% avg upside 19 analysts	$40.00 516.25% Upside	-4.8%	·
IMMX Immix Biopharma	Sep 29, 2026	BUY	Strong Buy +179.7% avg upside 9 analysts	$30.00 290.71% Upside	-23.5%	·
SRPT Sarepta Therapeutics	Sep 28, 2026	SELL	Buy +223.8% avg upside 50 analysts	—	+5.2%	·
ABSI AbSci	Sep 23, 2026	BUY	Strong Buy +20.1% avg upside 20 analysts	$11.00 1.08% Downside	+10.8%	·
LYEL Lyell Immunopharma	Sep 11, 2026	BUY	Strong Buy +151.1% avg upside 12 analysts	$44.00 298.53% Upside	+28.9%	·
TCRX TScan Therapeutics	Sep 02, 2026	HOLD	Buy +4293.5% avg upside 12 analysts	—	-44.9%	·
FTH Faeth Therapeutics	Aug 21, 2026	BUY	Strong Buy +160.3% avg upside 22 analysts	$56.00 199.56% Upside	-31.1%	·
TSHA Taysha Gene Therapies	Aug 12, 2026	BUY	Strong Buy +241.9% avg upside 22 analysts	$12.00 190.57% Upside	-33.3%	·
MREO Mereo Biopharma Group Plc	Aug 11, 2026	BUY	Strong Buy +1238.5% avg upside 11 analysts	$3.00 936.27% Upside	-3.2%	·
SLDB Solid Biosciences	Aug 07, 2026	BUY	Strong Buy +176.4% avg upside 26 analysts	$19.00 206.44% Upside	-21.4%	·
IMCR Immunocore Holdings	Aug 06, 2026	BUY	Strong Buy +109.0% avg upside 22 analysts	$75.00 146.06% Upside	-7.2%	·
GERN Geron	Aug 05, 2026	BUY	Strong Buy +371.7% avg upside 19 analysts	$4.00 347.15% Upside	-33.7%	·
NRIX Nurix Therapeutics	Aug 04, 2026	BUY	Strong Buy +22.5% avg upside 28 analysts	$34.00 26.95% Upside	-35.6%	·
STTK Shattuck Labs	Nov 07, 2025	HOLD	Strong Buy +276.2% avg upside 16 analysts	—	+143.4%	·
NBP NovaBridge Biosciences	Oct 24, 2025	HOLD	Strong Buy +1669.5% avg upside 14 analysts	—	-78.4%	·
NXTC NextCure	Dec 27, 2024	HOLD	Buy +182.1% avg upside 10 analysts	—	-45.8%	·
GB:0DPB Bavarian Nordic AS	Feb 16, 2023	BUY	Strong Buy +42.5% avg upside 5 analysts	$371.00 50.37% Upside	-26.2%	·
TECX Tectonic Therapeutic	Dec 07, 2022	BUY	Strong Buy +176.5% avg upside 24 analysts	$6.00 69.75% Downside	+449.9%	·
SYRE Spyre Therapeutics	Aug 25, 2022	HOLD	Strong Buy +0.9% avg upside 25 analysts	—	+95.3%	·
ATHXQ Athersys	Jun 03, 2022	HOLD	Buy +2996428471.4% avg upside 8 analysts	—	·	·

🔒 23 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Gil Blum — Frequently Asked Questions

How accurate are Gil Blum's stock ratings?

Based on the calls 13Foresight could measure, about 43% of Gil's ratings were profitable over a one-year hold, with an average return of -1.9% per rating, or -3.4% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Gil ranked on 13Foresight?

Gil Blum is currently ranked #2406 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Gil cover?

Gil most recently has ratings on ARTV, RXRX, RCKT, FATE, NKTX, CRSP, AUTL, CELC, RNAC, IMMX, SRPT, ABSI and 16 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Gil Blum

Rating Distribution

Welcome to 13Foresight!